During the early launch months for Rezdiffra (resmetirom), Madrigal Pharmaceuticals is thinking both about the present and the future – juggling goals to build a market with the first approved drug for non-alcoholic steatohepatitis (NASH) and to leverage the first-mover advantage it claimed with US Food and Drug Administration approval in March.
Madrigal Shatters Street Expectations With $62m In Q3 Rezdiffra Sales
Doubling some analyst projections for its second full quarter on market, Madrigal’s NASH drug appears headed to blockbuster status and a sustained market position.
More from Earnings
• By
Sector-specific tariffs, including on pharmaceuticals, could be announced as early as this week.
• By
Industry lobbied for pharmaceuticals to be exempt from Trump’s sweeping US tariffs and the effort appears to have paid off. J&J, Lilly and Merck & Co. even got shout outs.
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
Pharma executives and investors are waiting with bated breath to find out if President Trump will include drugs in a new round of tariffs to be announced on 2 April.
More from Therapy Areas
• By
BeiGene’s Phase III ociperlimab joins the list of failed TIGIT inhibitors, as candidates from Roche, Merck & Co. and others have failed late-stage studies.
• By
The German firm’s chairman, Hubertus von Baumbach, is adopting a ‘wait-and-see’ approach to the threat of pharma tariffs.
• By
With new Phase II data, Edgewise asserted that EDG-7500, a sarcomere modulator, could offer better efficacy and safety than cardiac myosin inhibitors in hypertrophic cardiomyopathy.